Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabeled BIM23B065 mass balance and pharmacokinetics study in healthy male volunteers
NL-OMON43034Phase 1Active, not recruiting
- Sponsor
- Ipsen
- Start
- Oct 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BIM23B065 in pituitary adenoma, pituitary neoplasm and acromegaly, sponsored by Ipsen. Primary endpoints: Mass balance recovery of total radioactivity, Plasma pharmacokinetics of BIM23B065 and BIM23B133 and 1 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
BIM23B065
03
Conditions
pituitary adenomapituitary neoplasmacromegaly
Beyond the preview
Go deeper on NL-OMON43034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43034.